Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
'Phenoconversion' in adult patients with β-thalassemia.
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL; Webthal® project. Musallam KM, et al. Among authors: origa r. Am J Hematol. 2024 Mar;99(3):490-493. doi: 10.1002/ajh.27194. Epub 2024 Jan 2. Am J Hematol. 2024. PMID: 38165006
New case of contiguous gene syndrome at chromosome 8p11.2p12.
Cau M, Congiu R, Origa R, Galanello R, Melis MA, Nucaro AL. Cau M, et al. Among authors: origa r. Am J Med Genet A. 2005 Jul 15;136(2):221-2. doi: 10.1002/ajmg.a.30814. Am J Med Genet A. 2005. PMID: 15948194 No abstract available.
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Taher AT, et al. Among authors: origa r. Br J Haematol. 2015 Jan;168(2):284-90. doi: 10.1111/bjh.13119. Epub 2014 Sep 12. Br J Haematol. 2015. PMID: 25212456 Free article. Clinical Trial.
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kilinç Y, Perrotta S, Karakas Z, Viprakasit V, Habr D, Constantinovici N, Shen J, Porter JB; HYPERION Investigators. Aydinok Y, et al. Among authors: origa r. Blood. 2015 Jun 18;125(25):3868-77. doi: 10.1182/blood-2014-07-586677. Epub 2015 May 1. Blood. 2015. PMID: 25934475 Free PMC article. Clinical Trial.
Survival and complications in thalassemia.
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A. Borgna-Pignatti C, et al. Among authors: origa r. Ann N Y Acad Sci. 2005;1054:40-7. doi: 10.1196/annals.1345.006. Ann N Y Acad Sci. 2005. PMID: 16339650 Review.
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Piga A, et al. Among authors: origa r. Haematologica. 2006 Jul;91(7):873-80. Haematologica. 2006. PMID: 16818273 Clinical Trial.
90 results